NCT07341763 Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment
| NCT ID | NCT07341763 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Waterloo |
| Condition | Retinitis Pigmentosa (RP) |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-07-01 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2026-07-01 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This pilot clinical trial evaluates whether non-invasive brain stimulation improves the orientation and mobility (O\&M) skills of individuals with constricted visual fields in both eyes. The study is composed of three visits. The first visit is meant to confirm eligibility by performing a few clinical tests. Eligible participants will then complete two additional visits, one in which the participants receive active stimulation, and one in which the participants receive placebo (sham) stimulation. Stimulation will be administered in a randomized, double-blind order. To evaluate improvement, various measures of O\&M performance will be assessed on a standardized obstacle course featuring static natural and artificial obstacles at defined intervals after the intervention. We hypothesize that the application of hf-tRNS to V1 will improve the orientation and mobility skills of individuals with constricted visual fields immediately following stimulation as a results of enhanced periphery through modulation of the mechanisms responsible for crowding, thereby reducing crowding effects and improving contrast for individuals with rod-cone dystrophy and RP (genetic conditions), whereas for individuals with glaucoma (a neurogenerative condition), any improvement noted would be attributed to be enhanced processing of visual signal in the affected periphery. The results will inform the design of a future, larger-scale study.
Eligibility Criteria
Inclusion Criteria: * Are healthy, capacitated adults with binocular constricted visual field loss (due to either retinitis pigmentosa (RP), rod-cone dystrophy, or advanced glaucoma) resulting in functional vision losses. These individuals with visual impairments can be those who have been previously trained by an Orientation and Mobility (O\&M) specialist to independently travel with the long white cane daily (since the length of the white cane and tip at the base are based on personal preference, they should be willing to use their own white cane for the study), and those who do not necessarily use a cane for travelling. * Have binocular visual acuity or best corrected binocular visual acuity no worse than 6/12 or 20/40 or +0.30 logMAR (inclusive) with no eccentric viewing and binocular visual fields no better than 50 degrees in total in each eye as given by the Humphrey Field analyzer and no better than 50 degrees binocularly as given by arc perimeter test. The Humphrey Field Analyzer measures static visual field test, whereas the Arc perimeter test measures kinetic visual field test. Measuring kinetic and static visual field would promote a greater understanding of the individual's daily performance. * Are over the age of 18 (inclusive) and has full legal capacity to provide informed consent. * Have read and fully comprehends the information in the consent letter. * Are willing and capable of adhering to instructions and maintaining the outlined appointment schedule. Exclusion Criteria: * Are involved in other recent eye-related studies, either clinical or research-related. To be eligible they would have to wait at least one week for studies not involving brain stimulation, and four weeks for studies in which they receive brain stimulation before they could participate in this study. * Have been diagnosed with dementia or self-reported dementia with no formal diagnosis. * Have been diagnosed with a cognitive impairment or self-reported cognitive impairment with no formal diagnosis. * Have been diagnosed with physical or motor impairments resulting in walking and/or balancing issues or self-reported physical or motor impairments resulting in walking and/or balancing issues with no formal diagnosis. * Have been diagnosed with vestibular disorders or dysfunctions which affects one's balance and/or mobility or self-reported vestibular disorders or dysfunctions which affects one's balance and/or mobility with no formal diagnosis. * Are unable to follow the researcher's instructions. * Are anticipating treatment (including ocular surgery) for any eye disease within the duration of the study. * Have any ocular pathology in addition to retinitis pigmentosa (RP), rod-cone dystrophy, or advanced glaucoma, which can diminish their visual acuity and/or their visual field, however wearing glasses or contact lenses, as well as mild cataract of grade 2 or below is acceptable. * Have severe hearing impairment. * Are pregnant or trying to get pregnant. * Fit any of the typical contraindicators for brain stimulation. See contraindicator section below. For all participants the contraindications for brain stimulation are: * Diagnosed with epilepsy or have previously experienced an epileptic seizure. * Implanted medication pump or implanted electronic device, including defibrillator or pacemaker. * Any metal implants in the head (excluding tooth fillings). * Active electric implants anywhere in the body (especially the head region). * On psychoactive medication for any psychiatric or neurological conditions including but not limited to depression and schizophrenia. * Areas of sensitive skin located on the face or head, or a skin condition on the face, or regularly use medication to alleviate skin irritation on the face. * Recurring headaches. * Previous head injury or skull fracture or head/brain surgery. * Heart disease, neurological condition, or a history of cardiac or neurological surgery. * Current or historical cancerous or noncancerous brain tumor, or other abnormalities in brain structure.
Contact & Investigator
Benjamin Thompson, PhD
PRINCIPAL INVESTIGATOR
University of Waterloo School of Optometry and Vision Science
Frequently Asked Questions
Who can join the NCT07341763 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Retinitis Pigmentosa (RP). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07341763 currently recruiting?
Yes, NCT07341763 is actively recruiting participants. Contact the research team at ben.thompson@uwaterloo.ca for enrollment information.
Where is the NCT07341763 trial being conducted?
This trial is being conducted at Waterloo, Canada.
Who is sponsoring the NCT07341763 clinical trial?
NCT07341763 is sponsored by University of Waterloo. The principal investigator is Benjamin Thompson, PhD at University of Waterloo School of Optometry and Vision Science. The trial plans to enroll 20 participants.